Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by Hills Bank & Trust Co

Hills Bank & Trust Co lessened its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 0.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 25,418 shares of the medical equipment provider’s stock after selling 185 shares during the quarter. Hills Bank & Trust Co’s holdings in Zimmer Biomet were worth $3,093,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. American Century Companies Inc. grew its holdings in shares of Zimmer Biomet by 21.2% in the third quarter. American Century Companies Inc. now owns 4,863,741 shares of the medical equipment provider’s stock valued at $545,809,000 after purchasing an additional 852,186 shares during the period. Boston Partners grew its holdings in shares of Zimmer Biomet by 29.2% during the 3rd quarter. Boston Partners now owns 2,694,832 shares of the medical equipment provider’s stock worth $302,366,000 after purchasing an additional 608,959 shares during the period. Barclays PLC increased its position in shares of Zimmer Biomet by 129.2% during the 3rd quarter. Barclays PLC now owns 1,072,494 shares of the medical equipment provider’s stock worth $120,356,000 after purchasing an additional 604,652 shares during the last quarter. Van ECK Associates Corp raised its holdings in Zimmer Biomet by 23.7% in the 4th quarter. Van ECK Associates Corp now owns 2,838,558 shares of the medical equipment provider’s stock valued at $345,452,000 after buying an additional 543,344 shares during the period. Finally, Qube Research & Technologies Ltd purchased a new position in Zimmer Biomet during the third quarter worth about $57,972,000. 88.89% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ZBH has been the subject of a number of research analyst reports. StockNews.com cut shares of Zimmer Biomet from a “strong-buy” rating to a “buy” rating in a research report on Monday, February 19th. Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a research report on Thursday, May 2nd. Truist Financial reduced their target price on shares of Zimmer Biomet from $137.00 to $130.00 and set a “hold” rating on the stock in a report on Friday, May 3rd. Barclays increased their price objective on Zimmer Biomet from $120.00 to $130.00 and gave the company an “underweight” rating in a research note on Monday, February 12th. Finally, JPMorgan Chase & Co. upped their price target on Zimmer Biomet from $115.00 to $125.00 and gave the stock a “neutral” rating in a report on Friday, February 9th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $135.40.

Insider Buying and Selling

In related news, VP Chad F. Phipps sold 26,156 shares of the business’s stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $128.62, for a total value of $3,364,184.72. Following the sale, the vice president now directly owns 44,145 shares of the company’s stock, valued at approximately $5,677,929.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.70% of the stock is owned by insiders.

Zimmer Biomet Stock Performance

Shares of Zimmer Biomet stock traded down $0.22 during trading on Friday, reaching $121.22. The company’s stock had a trading volume of 372,993 shares, compared to its average volume of 1,455,129. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.80 and a current ratio of 1.66. The firm has a market cap of $24.94 billion, a price-to-earnings ratio of 26.32, a price-to-earnings-growth ratio of 2.18 and a beta of 1.03. The business’s fifty day moving average price is $125.01 and its 200-day moving average price is $120.44. Zimmer Biomet Holdings, Inc. has a one year low of $102.00 and a one year high of $147.50.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.87 by $0.07. The firm had revenue of $1.89 billion during the quarter, compared to the consensus estimate of $1.87 billion. Zimmer Biomet had a return on equity of 12.70% and a net margin of 12.93%. The business’s revenue for the quarter was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.89 EPS. As a group, equities research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.09 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, April 30th. Investors of record on Friday, March 29th were given a $0.24 dividend. The ex-dividend date was Wednesday, March 27th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.79%. Zimmer Biomet’s dividend payout ratio is 20.78%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.